by Michaeline Daboul | Mar 2, 2017 | FCPA, UK Bribery Act, US Regulatory Compliance
Michaeline Daboul, Matthew Stephenson, and Linda D. Bentley are interviewed by Bloomberg BNA’s John T. Aquino. Learn what experts in the life sciences industry are saying about biopharma compliance to foreign bribery laws and the US FCPA in the age of Trump.
by Michaeline Daboul | Mar 1, 2017 | FCPA, US Regulatory Compliance
Find out what experts, including Michaeline Daboul, CEO of MMIS, thinks about the future of the foreign corruption law and its influence in the life sciences industry as President Donald J. Trump sets out to de-regulate business.
by Michaeline Daboul | Feb 21, 2017 | US Regulatory Compliance
Will Trump repeal the ACA and along with it Open Payments aka the Sunshine Act? If sections of the ACA are repealed and Trumpcare replaces Obamacare, will Open Payments become more onerous or disappear? This post examines the evolution of Open Payments and the evolving healthcare transparency ecosystem which now includes 38 countries. How will Trump’s policies affect life sciences companies that operate in the US?